Wednesday, April 29, 2020 | 1:00 p.m. to 2:00 p.m. ET
This webinar is FREE.
|
FDA’s Postmarketing Adverse Drug Experience (PADE) Compliance Program monitors industry compliance with postmarketing laws and regulations for products regulated by the Center for Drug Evaluation and Research (CDER) to ensure that accurate, reliable, and timely safety data is submitted to FDA and available to reviewers who use this data to evaluate product safety. This webinar provides an overview of the PADE Compliance Program, as well as discusses inspection findings and trends from PADE inspections completed in Fiscal Year 2019 (October 1, 2018 to September 30, 2019).
TOPICS COVERED
INTENDED AUDIENCE
LEARNING OBJECTIVES
|
CONTINUING EDUCATION
This course:
|
jueves, 2 de abril de 2020
CDER SBIA Webinar: Postmarketing Drug Safety Compliance: 2019 Inspection Findings – Apr. 29, 2020
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario